FTFei Teng

Fei Teng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fei Teng has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Chen

    Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

    1 shared publication
  • Hanshu Liu

    Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases , Beijing

    1 shared publication
  • Hua Zheng

    Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases , Beijing

    1 shared publication
  • Hui Lu

    Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    1 shared publication
  • Jian Li

    Department of Hematology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    1 shared publication
  • Ke Zheng

    Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases , Beijing

    1 shared publication

Latest Publications

  • Open Access

    Kidney involvement in idiopathic multicentric Castleman disease–TAFRO syndrome: clinical spectrum, pathology and outcomes

    by Shuo Zhang, Hanshu Liu, Siyuan Li, Yubing Wen, Wenling Ye, Wei Ye, Hua Zheng, Lubin Xu, Fei Teng, Ying Wang, et al.

    Background: Idiopathic multicentric Castleman disease–thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly syndrome (iMCD-TAFRO) is a clinically aggressive subtype. Renal involvement and its impact on prognosis are poorly characterized. We aimed to describe renal clinicopathological features and outcomes in a large iMCD-TAFRO cohort. Methods: This 10-year retrospective cohort study enrolled iMCD-TAFRO patients at Peking Union Medical College Hospital. Renal involvement was defined by iMCD consensus criteria. Survival was analyzed using Kaplan–Meier methods. Results: A total of 48 patients (70.8% male; mean age 45 ± 15 years) were included. Renal involvement was observed in 95.8% (46/48) of the patients, presenting predominantly with reduced urine output, mild hematuria and proteinuria, as well as elevated serum creatinine. Acute kidney injury (AKI) occurred in 80.4% (37/46) of patients showing renal involvement and 37.8% of them required renal replacement therapy. Renal biopsies (n = 7) revealed glomerular microangiopathy in six cases. AKI was associated with elevated C-reactive protein (CRP) and D-dimer levels, and CRP levels correlated with peak serum creatinine levels. Therapy targeting the iMCD was mainly bortezomib, cyclophosphamide and dexamethasone regimen (31/48, 64.6%) with/without anti-interleukin-6 therapy. Nine patients died within hospital or during follow-up. Among AKI patients, 28/37 (75.7%) showed full recovery of renal function. Despite worse renal function at baseline, no significant survival difference was observed between dialyzed and non-dialyzed patients. Conclusions: Renal involvement in iMCD-TAFRO is common and frequently manifests as AKI associated with systemic inflammation. Early and aggressive therapy combined with supportive renal care, including timely dialysis, improved renal recovery and overall prognosis.

  • Open Access

    Urinary System Manifestation of IgG4‐Related Disease: Clinical, Laboratory, Radiological, and Pathological Spectra of a Chinese Single‐Centre Study

    by Fei Teng, Hui Lu, Ke Zheng, Gang Chen, Yubing Wen, Zheng Liu, Linyi Peng, Li Huo, Xiaofeng Zeng, Wen Zhang, et al.

    Background . IgG4‐related disease is a new disease entity, but little attention was drawn to urinary system involvement besides nephritis or nephropathy. Here, we described clinical, radiological, and pathological manifestations of IgG4‐related urinary disease (IgG4‐RUD) and assess its treatment responses. Methods . We conducted a retrospective study enrolling 65 IgG4‐RUD patients from an IgG4‐related disease (IgG4‐RD) cohort of the Peking Union Medical College Hospital. Clinical, laboratory, radiological, pathological data were collected, and treatment response to immunosuppressants were analysed. Results . IgG4‐related interstitial nephritis (TIN, 32.3%), glomerular nephritis (GN, 7.7%), renal pelvis and ureter involvement (21.5%), abnormal radiology with quiescent clinical presentation (13.8%), and renal parenchymal lesion plus retroperitoneal fibrosis (RPF, 18.5%) were major lesion types of IgG4‐RUD. All patients had elevated serum IgG4, 76.9% had hyperglobulinemia, and 92.3% had elevated serum IgE at diagnosis. IgG4‐TIN patients presented with renal dysfunction, and 94.3% had low serum complement C3 and IgG4‐GN presented with nephrotic syndrome, while renal pelvis and ureter involvement had normal renal function and urinalysis. IgG4‐RPF with renal parenchymal involvement presented with acute renal dysfunction and required emergency medical intervention. Renal cortex low‐density areas, parenchyma or pelvis nodular mass, bilateral enlargement of the kidney, and renal pelvis and ureter mass/wall thickening were specific image patterns of IgG4‐RUD. Infiltration of plasma lymphocytes and storiform fibrosis were histopathological features of IgG4‐RUD. Patients showed satisfactory responses to immunosuppressive treatment, but complete recovery of renal function was difficult to achieve in IgG4‐TIN. Four patients (6.2%) experienced clinical relapses during the maintenance period. Conclusion . IgG4‐RUD had diverse lesion types and distinctive manifestations. Radiological examinations were helpful for diagnosis and treatment evaluation. Patients showed good initial response to immunosuppressive treatment but relapses could occur at the maintenance period.